ArticleNutrition & metabolism2026
Effects of regular consumption of a β-glucan-rich oyster mushroom powder on cholesterol metabolism in adults with moderately elevated LDL-cholesterol concentrations: a double-blind randomized controlled trial.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Edible Mushroom Polysaccharides as Functional Food Ingredients for Metabolic Health: Preparation, Techno-Functional Behavior, and Requirements for Translation.Foods (Basel, Switzerland) · 2026Review
- Medicinal mushrooms and type 2 diabetes: mechanistic insights, translational evidence, and clinical caveats.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOyster mushrooms (Pleurotus ostreatus, PO) are rich in β-glucans and other ingredients with cholesterol-lowering potential. While human intervention studies suggest that PO intake may reduce total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides, current evidence remains limited due to methodological limitations of the studies. Thus, this study investigated whether regular intake of PO powder affects LDL-C concentrations in adults with moderately elevated LDL-C (primary aim). Moreover, the study explored the effect on other lipids (TC, high-density lipoprotein cholesterol, triglycerides), on apolipoproteins A1 and B and possible underlying mechanisms of action (secondary aims).
methodsIn a double-blind, randomized controlled trial, 46 adults (37 female, 9 male) with moderately elevated LDL-C (116-190 mg/dL) consumed a beverage containing 8.4 g PO powder providing 3 g of β-glucans or a beverage without PO daily over 4 weeks. Plasma concentrations of LDL-C, other lipids and apolipoproteins were measured before and after intervention. The concentrations of noncholesterol sterols in serum, normalized to cholesterol, were determined as validated surrogate markers for cholesterol absorption (sitosterol, campesterol, and 5α-cholestanol), cholesterol synthesis (lathosterol), and bile-acid synthesis (7α-hydroxycholesterol), along with ergosterol, a fungal-specific sterol. Expression of selected target genes involved in cholesterol metabolism was analyzed in blood. Statistical analysis included comparisons of the changes between the groups (treatment effect) and linear modeling.
resultsPO treatment did not modulate LDL-C; no treatment effect was observed for other lipids, apolipoproteins or gene expression (P ≥ 0.05 for all). However, after adjustment for sex, linear model analysis showed a reduction in markers of cholesterol absorption, especially in females (P < 0.05 for all). No effects were observed on markers of cholesterol and bile-acid synthesis (P ≥ 0.05 for all). Ergosterol was detectable in all serum samples after PO intake, confirming high compliance with PO treatment.
conclusionsDaily consumption of 8.4 g of PO powder over 4 weeks has no impact on LDL-C concentrations in adults with moderately elevated LDL-C concentrations. However, post-hoc analysis indicates a sex-dependent reduction in cholesterol absorption by PO consumption, especially in females, suggesting that PO may have the potential to beneficially modulate cholesterol metabolism.
trial registrationRegistration at German Clinical Trials Register; DRKS-ID: DRKS00033943; registration date: 21/03/2024. https://drks.de/search/de/trial/DRKS00033943 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.